REFERENCES
  1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China [published online ahead of print, 2020 Feb 28]. N Engl J Med. 2020;10.1056/NEJMoa2002032.
  2. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China [published online ahead of print, 2020 Feb 19]. Allergy. 2020;10.1111/all.14238.
  3. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China [published online ahead of print, 2020 Mar 25]. JAMA Cardiol. 2020;e200950.
  4. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? [published online ahead of print, 2020 Mar 11]. Lancet Respir Med. 2020;S2213-2600(20)30116-8.
  5. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
  6. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43(5):970–976.
  7. Ocaranza MP, Godoy I, Jalil JE, et al. Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension. 2006;48(4):572–578.
  8. Hristova M, Stanilova S, Miteva L. Serum concentration of renin-angiotensin system components in association with ACE I/D polymorphism among hypertensive subjects in response to ACE inhibitor therapy. Clin Exp Hypertens. 2019;41(7):662–669.
  9. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin-converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–879.
  10. Kow CS, Zaidi STR, Hasan SS. Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19 [published online ahead of print, 2020 Apr 13]. Am J Cardiovasc Drugs. 2020;10.1007/s40256-020-00406-0.
  11. Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 [published online ahead of print, 2020 Apr 17]. Circ Res. 2020;10.1161/CIRCRESAHA.120.317134.
  12. Lee H, Ahn J, Kang CK, et al. Association of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19-related outcome. 2020. Available at SSRN: https://ssrn.com/abstract=3569837 (21 April 2020)
  13. Yang G, Tan Z, Zhou L, et al. Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study [published online ahead of print, 2020 Apr 29]. Hypertension. 2020;10.1161/HYPERTENSIONAHA.120.15143.
  14. Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–760.
  15. Feng Z, Li J, Yao S, et al. The use of adjuvant therapy in preventing progression to severe pneumonia in patients with coronavirus disease 2019: a multicenter data analysis. 2020. medRxiv 2020.04.08.20057539
  16. Peng YD, Meng K, Guan HQ, et al. Clinical features and outcome of 112 cases of novel coronavirus pneumonia in cardiovascular patients [Chinese]. Chin. J. Cardiol. 2020;48.
  17. Chen M, Fan Y, Wu X, et al. Clinical Characteristics And Risk Factors For Fatal Outcome in Patients With 2019-Coronavirus Infected Disease (COVID-19) in Wuhan, China. 2020. Available at SSRN: https://ssrn.com/abstract=3546069 (21 April 2020)
  18. Huang Z, Cao J, Yao Y, et al. The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. Ann Transl Med. 2020;8(7):430.
  19. Zeng Z, Sha T, Zhang Y et al. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: a single-center retrospective observational study. medRxiv 2020.04.06.20054825
  20. Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China [published online ahead of print, 2020 Apr 23]. JAMA Cardiol. 2020;10.1001/jamacardio.2020.1624.
  21. Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv 2020.03.20.20039586
  22. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 [published online ahead of print, 2020 May 1]. N Engl J Med. 2020;10.1056/NEJMoa2007621.
  23. Ip A, Parikh K, Parrillo JE, et al. Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. medRxiv 2020.04.24.20077388
Table 1: Summary of studies examining the mortality and critical/severe disease in ACE inhibitor/ARB exposed and unexposed groups